SeekingAlpha · Oct 27, 2026
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven
Autolus Therapeutics' Q2 2026 saw a 74% sales jump to $45.7M and a gross margin expansion to 55%. I rate AUTL stock as Hold. Click to read my full analysis.
NASDAQ · AUTL
Autolus Therapeutics plc
Healthcare · Biotechnology
$1.52
Down-$0.06 (-3.80%)
Updated Oct 31, 2026, 9:13 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 424.5M
- P/E ratio
- -1.86
- Dividend yield
- 0.00%
- 52-week range
- $1.18 – $2.58
- Volume
- 1.68M
- Avg. volume
- 3.54M
Price performance · AUTL
AUTL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
AUTL closed at $1.52 after 21 trading sessions, down 14.61% for the selected period.
- Last close
- $1.52
- Period change
- -14.61%
- Period low
- $1.52
- Period high
- $1.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.58 | $1.59 | $1.48 | $1.52 | 1.68M |
| Oct 29, 2026 | $1.63 | $1.65 | $1.57 | $1.58 | 2.35M |
| Oct 28, 2026 | $1.55 | $1.64 | $1.52 | $1.63 | 1.39M |
| Oct 27, 2026 | $1.53 | $1.56 | $1.50 | $1.55 | 1.79M |
| Oct 26, 2026 | $1.54 | $1.55 | $1.51 | $1.53 | 1.24M |
| Oct 23, 2026 | $1.58 | $1.58 | $1.50 | $1.54 | 1.53M |
| Oct 22, 2026 | $1.63 | $1.64 | $1.5301 | $1.58 | 1.92M |
| Oct 21, 2026 | $1.68 | $1.685 | $1.61 | $1.62 | 1.83M |
| Oct 20, 2026 | $1.59 | $1.68 | $1.575 | $1.66 | 2.64M |
| Oct 19, 2026 | $1.59 | $1.60 | $1.54 | $1.59 | 1.52M |
| Oct 16, 2026 | $1.74 | $1.74 | $1.59 | $1.60 | 2.35M |
| Oct 15, 2026 | $1.70 | $1.74 | $1.68 | $1.72 | 1.49M |
| Oct 14, 2026 | $1.61 | $1.70 | $1.60 | $1.69 | 2.59M |
| Oct 13, 2026 | $1.74 | $1.74 | $1.60 | $1.62 | 2.42M |
| Oct 12, 2026 | $1.82 | $1.82 | $1.74 | $1.74 | 1.06M |
| Oct 9, 2026 | $1.75 | $1.82 | $1.73 | $1.81 | 1.48M |
| Oct 8, 2026 | $1.78 | $1.78 | $1.72 | $1.77 | 1.6M |
| Oct 7, 2026 | $1.78 | $1.81 | $1.73 | $1.81 | 1.55M |
| Oct 6, 2026 | $1.84 | $1.87 | $1.764 | $1.79 | 1.68M |
| Oct 5, 2026 | $1.78 | $1.86 | $1.75 | $1.83 | 2.52M |
| Oct 2, 2026 | $1.85 | $1.88 | $1.76 | $1.78 | 1.81M |
Latest AUTL news
The latest Smart Investors Daily articles mentioning AUTL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AUTL research
Overview
Company profile and research snapshot.
Company profile
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.87
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 9, 2026 | Needham | Buy | — |
| Mar 31, 2026 | Mizuho | Outperform | — |
| Mar 27, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 27, 2026
Autolus Therapeutics: Key Questions For The Near Term
Autolus Therapeutics looks undervalued as revenue grows and autoimmune catalysts near. Read here for a detailed analysis of AUTL stock.
Yahoo · Oct 26, 2026
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its third quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, November 10, 2026. Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT to discuss th
Yahoo · Oct 5, 2026
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
